Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate associations between dyspnea and clinical outcomes in patients with non-small cell lung cancer (NSCLC). Materials and Methods: From 2001 to 2014, we retrospectively reviewed the prospective lung cancer database of St. Paul’s Hospitalat the Catholic University of Korea. We enrolled patients with NSCLC and evaluated symptoms of dyspnea using modified Medical Research Council (mMRC) scores. Also, we estimated pulmonary functions and analyzed survival data. Results: In total, 457 NSCLC patients were enrolled, and 259 (56.7%) had dyspnea. Among those with dyspnea and whose mMRC scores were available (109 patients had no mMRC score), 85 (56.6%) patients had an mMRC score <2, while 65 (43.3%) had an mMRC score ≥2. Significant decreased pulmonary functions were observed in patients with dyspnea. In multivariate analysis, aging,poor performance status, advanced stage, low forced expiratory volume in 1 second (%), and an mMRC score ≥2 were found to be significant prognostic factors for patient survival. Conclusion: Dyspnea could be a significant prognostic factor in patients with NSCLC.
Abstract
Purpose: To investigate associations between dyspnea and clinical outcomes in patients with non-small cell lung cancer (NSCLC). Materials and Methods: From 2001 to 2014, we retrospectively reviewed the prospective lung cancer database of St. Paul’s Hospitalat the Catholic University of Korea. We enrolled patients with NSCLC and evaluated symptoms of dyspnea using modified Medical Research Council (mMRC) scores. Also, we estimated pulmonary functions and analyzed survival data. Results: In total, 457 NSCLC patients were enrolled, and 259 (56.7%) had dyspnea. Among those with dyspnea and whose mMRC scores were available (109 patients had no mMRC score), 85 (56.6%) patients had an mMRC score <2, while 65 (43.3%) had an mMRC score ≥2. Significant decreased pulmonary functions were observed in patients with dyspnea. In multivariate analysis, aging,poor performance status, advanced stage, low forced expiratory volume in 1 second (%), and an mMRC score ≥2 were found to be significant prognostic factors for patient survival. Conclusion: Dyspnea could be a significant prognostic factor in patients with NSCLC.
참고문헌 (23)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Luengo-Fernandez R, "Economic burden of cancer across the European Union: a population-based cost analysis", Lancet Oncol, 14, pp.1165~1174 (2013)
- National Lung Screening Trial Research Team, "Reduced lung-cancer mortality with low-dose computed tomographic screening", N Engl J Med, 365, pp.395~409 (2011)
- Walters S, "Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007", Thorax, 68, pp.551~564 (2013)
- Carlson LE, "Screening for distress, the sixth vital sign, in lung cancer patients: effects on pain, fatigue, and common problems--secondary outcomes of a randomized controlled trial", Psychooncology, 22, pp.1880~1888 (2013)
- Blanchon F, "4-year mortality in patients with non-small-cell lung cancer:development and validation of a prognostic index", Lancet Oncol, 7, pp.829~836 (2006)
- Vermaelen K, "Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer", Pulm Pharmacol Ther, 26, pp.544~554 (2013)
- Young RP, "COPD prevalence is increased in lung cancer, independent of age, sex and smoking history", Eur Respir J, 34, pp.380~386 (2009)
- Sarna L, "Impact of respiratory symptoms and pulmonary function on quality of life of long-term survivors of non-small cell lung cancer", Chest, 125, pp.439~445 (2004)
- Cella DF, "Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument", Lung Cancer, 12, pp.199~220 (1995)
- Thongprasert S, "Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS), 2011, pp.6, 1872~1880
- Nishimura K, "Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD", Chest, 121, pp.1434~1440 (2002)
- Vestbo J, "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary", Am J Respir Crit Care Med, 187, pp.347~365 (2013)
- Raghunathan TE, "A multivariate technique for multiply imputing missing values using a sequence of regression models", Surv Methodol, 27, pp.85~96 (2001)
- Charpidou AG, "Therapy-induced toxicity of the lungs:an overview", Anticancer Res, 29, pp.631~639 (2009)
- De Ruysscher D, "Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer", Radiother Oncol, 91, pp.353~359 (2009)
- Foroulis CN, "Simple laboratory parameters which can determine the clinical state of patients after pneumonectomy for lung cancer", J Thorac Oncol, 4, pp.55~61 (2009)
- Feinstein MB, "Current dyspnea among long-term survivors of earlystage non-small cell lung cancer", J Thorac Oncol, 5, pp.1221~1226 (2010)
- Denehy L, "Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer", J Thorac Oncol, 8, pp.1545~1550 (2013)
- Celli BR, "The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease", N Engl J Med, 350, pp.1005~1012 (2004)
- Hashimoto N, "Clinical impact of prevalence and severity of COPD on the de-cision-making process for therapeutic management of lung cancer patients", BMC Pulm Med, 14, pp.14~ (2014)
- Zhang J, "Prevalence of undiagnosed and undertreated chronic obstructive pulmonary disease in lung cancer population", Respirology, 18, pp.297~302 (2013)
- O’Donnell DE, "Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise", Chest, 141, pp.753~762 (2012)